Apollon Wealth Management LLC Purchases 22,722 Shares of AbbVie Inc. $ABBV

Key Points

• Apollon Wealth Management increased its AbbVie stake by 18.6% in the third quarter, purchasing 22,722 additional shares and bringing its holdings to 145,103 shares valued at approximately $38.0 million. Institutional investors collectively own 70.23% of AbbVie.
• AbbVie reported quarterly revenue of $16.99 billion and adjusted earnings of $3.65 per share, exceeding analyst expectations, while revenue rose 10.2% year over year. The company also declared a quarterly dividend of $1.73 per share, equivalent to a 2.4% yield.
• Analyst sentiment remains favorable, with AbbVie receiving a “Moderate Buy” consensus rating and an average price target of $279.86. Recent targets range as high as $310, although the stock’s elevated valuation and a reduced earnings forecast from Erste Group present potential risks.

Apollon Wealth Management LLC raised its holdings in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 18.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 145,103 shares of the company's stock after purchasing an additional 22,722 shares during the period. Apollon Wealth Management LLC's holdings in AbbVie were worth $37,957,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the stock. Burk Holdings LLC bought a new stake in AbbVie during the 2nd quarter valued at approximately $30,000. Marquette Asset Management LLC raised its position in shares of AbbVie by 52.2% in the 2nd quarter. Marquette Asset Management LLC now owns 140 shares of the company's stock worth $35,000 after acquiring an additional 48 shares in the last quarter. IMG Wealth Management Inc. raised its position in shares of AbbVie by 3,060.0% in the 2nd quarter. IMG Wealth Management Inc. now owns 158 shares of the company's stock worth $40,000 after acquiring an additional 153 shares in the last quarter. Principia Wealth Advisory LLC lifted its stake in shares of AbbVie by 38.9% in the 2nd quarter. Principia Wealth Advisory LLC now owns 157 shares of the company's stock valued at $40,000 after purchasing an additional 44 shares during the period. Finally, Tacita Capital Inc purchased a new position in shares of AbbVie in the 2nd quarter valued at approximately $42,000. Institutional investors own 70.23% of the company's stock.

AbbVie Stock Up 0.4%

ABBV stock opened at $286.88 on Tuesday. The business has a 50 day moving average of $266.18 and a 200 day moving average of $235.62. The firm has a market cap of $506.85 billion, a PE ratio of 26.28, a price-to-earnings-growth ratio of 1.30 and a beta of 0.24. AbbVie Inc. has a twelve month low of $190.75 and a twelve month high of $291.40.

AbbVie (NYSE:ABBV - Get Free Report) last released its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The business had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. During the same period in the previous year, the company posted $2.97 earnings per share. The company's revenue for the quarter was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, research analysts expect that AbbVie Inc. will post 13.93 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 2.4%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie's payout ratio is currently 195.48%.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on ABBV. Cantor Fitzgerald upped their price target on AbbVie from $285.00 to $290.00 and gave the stock an "overweight" rating in a research note on Thursday, October 8th. Rothschild & Co Redburn raised their price objective on AbbVie from $284.00 to $285.00 and gave the company a "buy" rating in a research report on Tuesday, August 4th. The Goldman Sachs Group boosted their target price on shares of AbbVie from $258.00 to $294.00 and gave the company a "neutral" rating in a report on Friday. Morgan Stanley boosted their target price on shares of AbbVie from $296.00 to $310.00 and gave the company an "overweight" rating in a report on Wednesday, October 7th. Finally, Canaccord Genuity Group upped their target price on shares of AbbVie from $282.00 to $290.00 and gave the stock a "buy" rating in a research report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $279.86.

Insider Activity

In other news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the transaction, the executive vice president owned 74,430 shares of the company's stock, valued at $18,607,500. The trade was a 30.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.06% of the stock is currently owned by corporate insiders.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The U.S. Food and Drug Administration approved a subcutaneous induction regimen for AbbVie’s SKYRIZI in adults with moderately to severely active Crohn’s disease. The needle-based treatment option may improve convenience and support the drug’s continued growth across immunology indications. FDA approves subcutaneous SKYRIZI regimen
• Positive Sentiment: Goldman Sachs raised its price target for ABBV to $294, signaling continued confidence in the company’s outlook and providing a bullish valuation reference. Goldman Sachs raises AbbVie price target
• Positive Sentiment: Reports that Citadel has built an approximately $900 million position in AbbVie may boost sentiment by highlighting institutional interest in the company’s dividend and growth profile. Citadel AbbVie position
• Neutral Sentiment: Options markets imply roughly a 5% move around the October 30 earnings release, indicating that investors expect significant volatility as they assess results and forward guidance. AbbVie options and earnings volatility
• Neutral Sentiment: Coverage continues to describe AbbVie as an attractive, income-focused “Dividend King,” although its high earnings multiple makes future performance dependent on sustained earnings growth. AbbVie Dividend King coverage
• Negative Sentiment: Erste Group Bank reduced its EPS forecast and expressed a weak outlook for AbbVie’s fiscal 2026 earnings, creating a counterweight to the favorable product and institutional news. Erste Group lowers AbbVie EPS forecast

About AbbVie

AbbVie Inc NYSE: ABBV is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company's key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.